Glufast mitiglinide: Phase III data

In a double-blind, U.S. Phase III trial (EX-1510-CT-003) in 350 patients, twice-daily oral mitiglinide plus metformin met the primary endpoint of a significant reduction in HbA1c from baseline vs. met...